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Abstract
Type 1 (insulin-dependent) diabetes mellitus, like other
organ specific autoimmune diseases, results from a disor-
der of immunoregulation. T cells specific for pancreatic
islet 6 cell constituents (autoantigens) exist normally but
are restrained by regulatory mechanisms (self-tolerant
state). When regulation fails, t cell-specific autoreactive T
cells become activated and expand clonally. Current evi-
dence indicates that islet t cell-specific autoreactive T cells
belong to a T helper 1 (Thl) subset, and these Thl cells
and their characteristic cytokine products, IFN and IL-2,
are believed to cause islet inflammation (insulitis) and tg
cell destruction. Immune-mediated destruction of fg cells
precedes hyperglycemia and clinical symptoms by many
years because these become apparent only when most of
the insulin-secreting fg cells have been destroyed.
Therefore, several approaches are being tested or are
under consideration for clinical trials to prevent or arrest
complete autoimmune destruction of islet g cells and
insulin-dependent diabetes. Approaches that attempt to
correct underlying immunoregulatory defects in autoim-
mune diabetes include interventions aimed at i) deleting t
cell autoreactive Thl cells and cytokines (IFN/and IL-2)
and/or ii) increasing regulatory Th2 cells and/or Th3 cells
and their cytokine products (IL-4, IL-10 and TGFfI).
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Type 1 Diabetes Viewed as a
Disorder of immunoregulation
Type 1 diabetes mellitus results from selective destruction
of the insulin-producing f cells in the pancreatic islets of
Langerhans. The current concept is that pancreatic islet f
cells are destroyed by an autoimmune response mediated
by T lymphocytes (T cells) that react specifically to one or
more f cell proteins (autoantigens). Ill Although it has not4 REVIEW
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A current formulation of the pathogenesis of type diabetes. Genetic and environmental factors inter-
act and confer either susceptibility or resistance to disease, depending the gene/allele possessed by
the individual and the environmental agent to which that individual is exposed. Disease susceptibili-
ty leads to a pathogenic immune response whereas disease resistance leads to a protective immune
response. The pathogenic immune response is believed to be mediated by T lymphocytes (T cells) that
are reactive to islet f cell self-antigen(s) (autoreactive T cells), whereas a protective immune response
may be mediated by T cells that suppress the autoreactive T cells (regulatory T cells). Dominance of
the pathogenic immune response would lead to islet inflammation (insulitis). This is characterized by
infiltration of the islet by macrophages and T cells that are cytotoxic, both directly and indirectly by
producing cytokines (e.g., IL-1, TNF0, TNFf, and IFN/) and free radicals that damage f cells.
Genetic and environmental factors may also directly increase or decrease the ability of f cells to repair
damage and prevent irreversible f cell death, insulinopenia, and diabetes. (Reproduced from
Rabinovitch A. and Skyler JS. Prevention of type diabetes 1998;82:739, with permission of W.B.
Saunders Co.)
been excluded that a primary f cell lesion, intrinsic or
acquired (possibly viral or chemical), might be involved in
initiating an autoimmune response,121 it is clear that, once
established, an immune response is the cause of f cell
destruction. For example, diabetes transfer studies have
demonstrated that bone marrow-derived cells from hosts
with autoimmune diabetes can transfer f cell destructive
insulitis to nondiabetes-prone human, mouse, or rat pan-
creas, thereby indicating that an underlying abnormality
in type 1 diabetes resides in the immune system.I3-81
The autoimmune response to islet f cells is thought to
occur in persons who possess certain
susceptibility alleles and who lack
other protective alleles of the major
histocompatibility (MHC) gene com-
plex, which regulates immune
responses. In addition, non-MHC
genes may contribute to the autoim-
mune response. The traditional con-
cept is that environmental factors
(e.g., microbial, chemical, dietary)
may trigger an autoimmune response
against f cells in a genetically dia-
betes-prone individual. Studies in
animal models with spontaneous
autoimmune diabetes, however, have
revealed that environmental factors
(particularly microbial agents) may
either promote or protect against
diabetes development. I91 Therefore,
the current concept being explored is
that both genetic and environmental
inputs may be either pathogenic (i.e.,
diabetes-promoting) or protective
against type 1 diabetes, and that dis-
ease appearance is influenced by the
net effects of genetic and environ-
mental factors on immune responses.
According to this concept, type 1 dia-
betes, like other organ-specific
autoimmune diseases, results from a
disorder of immunoregulation.Ill
This posits that T cells specific for
islet f cell molecules (i.e., autoanti-
gens) exist normally but are
restrained by immunoregulatory
mechanisms (the self-tolerant state),
and that type 1 diabetes develops
when one or another immunoregula-
tory mechanism (e.g., regulatory T
cells) fails, allowing f cell-autoreac-
tive T cells to become activated, expand clonally, and
entrain a cascade of immune and inflammatory processes
in the islets, culminating in tg cell destruction (Fig. 1).
Although it is not known what may trigger loss of self-
tolerance to islet antigens in type 1 diabetes, it appears
that defective immunoregulatory (suppressor) mecha-
nisms allow the autoimmune state to progress to a patho-
logical level and cause tg cell destruction. There is now
abundant evidence that suppressor cell defects may con-
tribute to diabetes development in rodent models of type
1 diabetes. In the nonobese diabetic (NOD) mouse, dia-
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betes onset is accelerated by thymectomy performed at 3
weeks of age11 and by administration of cyclophos-
phamide,II1,121 a drug known for its selective effects on
suppressor T cells. Diabetes transfer is obtained only in
immunodeficient recipients, that is, neonatesI3 and adults
that have been sublethally irradiatedI141 or thymectomized
and treated with a monoclonal antibody to CD4 T
cells.Isl One can prevent diabetes transfer by spleen cells
from diabetic mice by preinfusion of CD4 spleen cells
from nondiabetic syngeneic mice. 1161 CD4 and CD8 sup-
pressor clones have been reported,ll7-91 as has the produc-
tion of a suppressor factor.Ilgl Treatment of young NOD
mice with an anti-MHC class II monoclonal antibody pro-
tects them from diabetes, and this protection is transfer-
able to non-antibody-treated mice by infusion of CD4 T
cells from protected mice. I21 In the Biobreeding (BB) rat,
diabetes is accelerated by the administration of a mono-
clonal antibody to RT6.1 T cells 1211 and prevented by
transfusion of lymphoid cells from diabetes-resistant BB
rats. I=l Finally, the mechanisms by which islet autoreac-
tive T cells may be suppressed are unknown; however
recent studies have pointed to cytokines as important
immunoregulatory molecules.
Immune Responses: Roles of Cytokines
Cytokines are peptide molecules synthesized and secreted
by activated lymphocytes (lymphokines), macrophages/
monocytes (monokines) and cells outside the immune sys-
tem (e.g., endothelial cells, bone marrow stromal cells,
and fibroblasts). Cytokines are used mainly by immune
system cells to communicate with each other and to con-
trol local and systemic events of immune and inflamma-
tory responses. More than 30 immunologically active
cytokines exist and are generally grouped as interleukins
(ILs), interferons (IFNs), tumor necrosis factors (TNFs),
and colony-stimulation factors (CSFs).I31 Both the pro-
duction of cytokines by cells and the actions of cytokines
on cells are complex: A single cell can produce several dif-
ferent cytokines, a given cytokine can be produced by sev-
eral different cell types, and a given cytokine can act on
one or more cell types. Also, cytokine actions are usually
local: It can act i) between two cells that are conjugated to
one another, ii) on neighboring cells (paracrine), and iii)
on the cell that secretes the cytokine (autocrine). In some
cases (notably the macrophage-derived inflammatory
cytokines, such as IL-1, IL-6, and TNF0) cytokines exert
actions on distant organs (endocrine).
Interpretation of the actions of cytokines in general is
complicated by the very nature of cytokine biology. First,
large amounts of a cytokine are often produced when a
cell is stimulated by an antigen, mitogen, or other
cytokines (e.g., up to 2% of cell protein synthesis can be
devoted to a single cytokine). Second, cytokine receptors
have high affinities for their specific cytokine ligands, so
most cytokines have very high specific activity. The con-
sequences of these properties of cytokines and cytokine
receptors is that one activated cell can produce enough
cytokine to activate 1,000 10,000 other cells. (i.e., a very
small number of antigen-reactive cells can have wide-
spread effects). Third, cytokine synthesis is regulated by
the differentiation of cells into the various cytokine-secret-
ing phenotypes and by the selective activation of different
cell types to produce some or all of their characteristic set
of cytokines.
Antigen-activated T cells are termed T helper (Th) cells
because they help to mediate both cellular and humoral
(antibody) immune responses. In 1986, Mosmann and
colleagues,I241 started a conceptual revolution in immunol-
ogy by dividing T helper (Th) cells into two populations
with contrasting and crossregulating cytokine profiles.
The Thl and Th2 patterns of cytokine production were
originally described among mouse CD4 T cell clones124,2sl
and later among human T cells. 1261 Mouse Thl cells pro-
duce IL-2, IFN,, and TNFfl (also termed lymphotoxin),
whereas Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10
and IL-13. Cytokine production by human Thl and Th2
cells follows similar patterns, although the synthesis of IL-
2, IL-6, IL-10 and IL-13 is not as tightly restricted to a sin-
gle subset as in mouse T cells. Several other proteins are
secreted both by Thl and Th2 cells, including IL-3,
TNFcz, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and members of the chemokine families.I2vl
Thl and Th2 responses are not the only cytokine patterns
possible: T cells expressing cytokines of both patterns
have been called Th0 cellsI281 and those producing high
amounts of transforming growth factor f (TGFtg) have
been termed Th3. i291
The functional significance of Thl and Th2 cell subsets
is that their distinct patterns of cytokine secretion lead to
strikingly different T cell actions. 127,28,3-321 Thl cells and
their cytokine products (IL-2, IFN/and TNFf) are the
mediators in cell-mediated immunity (formerly termed
delayed-type hypersensitivity). IFN, and TNFig activate
vascular endothelial cells to recruit circulating leukocytes
into the tissues at the local site of antigen challenge, and
they activate macrophages to eliminate the antigen-bear-
ing cell. In addition, IL-2 and IFN, activate i) cytotoxic T
cells to destroy target cells expressing the appropriate
MHC-associated antigen, and ii) natural killer (NK) cells
to destroy target cells in an MHC-independent fashion.
Thus, Thl cytokines activate cellular immune responses.
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In contrast, Th2 cytokines are much more effective stimu-
lators of humoral immune responses, i.e., immunoglobu-
lin (antibody) production, especially immunoglobulin E,
by B cells. Furthermore, responses of Thl and Th2 cells
are mutually inhibitory. Thus, the Thl cytokine IFN/
inhibits the production of the Th2 cytokines IL-4 and IL-
l0; these, in turn, inhibit Thl cytokine production.
Protective responses to pathogens depend on activa-
tion of the appropriate Th subset accompanied by its
characteristic set of immune effector functions. For exam-
ple, human Thl cells develop in response to intracellular
bacteria and viruses, whereas Th2 cells develop in
response to allergens and helminth components.I31 Thl
and Th2 cells play different roles not only in protection
against exogenous offending agents, but also in
immunopathology. Thl cells are involved in contact der-
matitis, organ-specific autoimmunity, and allograft rejec-
tion, whereas Th2 cells are responsible for initiation of the
allergic cascade. I31
Among signals that may orient the immune response in
the direction of either a Thl or a Th2 cell response, the
macrophage-derived cytokines, IL-10 I331 and IL_121341 have
been discovered to play important roles. IL-12 is a potent
stimulant of Thl cells and cytokines, notably IFN,. Thus,
IL-12 can initiate cell-mediated immunity. In contrast, IL-
l0 (derived from macrophages and Th2 cells) exerts anti-
inflammatory effects by inhibiting production of IL-12
and other pro-inflammatory macrophage cytokines (e.g.,
IL-1, IL-6, IL-8, TNF0t), by increasing macrophage pro-
duction of IL-1 receptor antagonist, and by inhibiting the
generation of oxygen and nitrogen free radicals by
macrophages. In addition, IL-10 may favor Th2 over Thl
cell differentiation and function by inhibiting expression
ofMHC class II molecules and the B7 accessory molecule
on macrophages, a major costimulator of T cells. I3sl The
combination of IL-4 and IL-10 is particularly effective in
inhibiting Thl effector function (i.e., cell-mediated immu-
nity) in vivo. [36]
Thl-like and Th2-1ike polarized cytokine secretion
patterns have now been described for many different cell
types: CD4, CD8 and ,15 T cells, NK cells, B cells, den-
dritic cells, macrophages, mast cells and eosinophils.13vl In
recognition of the fact that cytokine secretion patterns are
not restricted to certain cell types, they are often described
as type 1 and type 2 rather than Thl and Th2. Thus a
cytokine can be classified on the basis of the response it
evokes rather than on the cell type that produces it. I381
Type 1 cytokines (IFN/, IL-2, TNFf and IL-12) primarily
stimulate cell-mediated immunity; type 2 cytokines (IL-4,
IL-5, IL-6, IL-10 and IL-13) primarily induce humoral
immunity and diminish cellular immunity; and the type 3
cytokine (TGFf) also diminishes cellular immunity. IL-1
(both 0t and 1 isoforms) and TNF are primarily, but not
exclusively macrophage-derived cytokines, and are gener-
ally referred to as proinflammatory cytokines.
Autoimmune Diabetes: A Dominance
of Th/ Over Th2 Cells?
There is now abundant evidence that autoreactive T cells
are present in the normal immune system but are prevent-
ed from expressing their autoreactive potential by other
regulatory (suppressor) T cells. For example, reconstitu-
tion of lymphopenic, prediabetic BB rats with the IL-4-
producing CD4 CD45RClw subset of Th cells but not
with the IL-2-producing CD4 CD45RChigh Th subset pro-
tects against autoimmune diabetes. 139 In a different
model, adult thymectomy combined with sublethal irradi-
ation causes diabetes in a nonautoimmune diabetes-prone
rat strain, and insulitis and autoimmune diabetes are com-
pletely prevented by injection of CD4 CD45RCw T cells
that secrete IL-2 and IL-4, not IFN]t. [39,41 Diabetes can be
adoptively transferred into neonatal NOD mice or
immunocompromised NOD-scid by splenic cells from
diabetic NOD mice, whereas splenic cells from young
nondiabetic NOD mice can prevent diabetic splenic cells
from adoptively transferring disease. Interestingly, both
the pathogenic and protective functions of CD4 cells in
the diabetic and nondiabetic NOD donor spleens were
found to reside in a CD45RBlw subset of CD4 T cells;
however, the pathogenic cells had a significantly higher
IFN//IL-4 production ratio than did the protective
ones. 1411 These findings support the concept that Thl cells
(IFN$-producing) are pathogenic and Th2 cells (IL-4-pro-
ducing) prevent diabetes development; however, diabetes
transfer and prevention were observed using polyclonal
populations of T cells, and the autoimmune response in
type 1 diabetes is believed to be dependent on T cells
specifically reactive to islet f-cell autoantigens.
A variety of islet-reactive T cell lines and clones that
either adoptively transfer diabetes or prevent against its
development inNOD mice have been described, and some
of these T cell lines/clones have been characterized in
terms of their cytokine production profiles. In one study,
CD4 T cells reactive to the islet autoantigen, glutamic
acid decarboxylase (GAD), were reported to secrete IFN,,
TNF0t, and TNFf, but not IL-4 in response to GAD anti-
gen, and these cells adoptively transferred diabetes into
NOD-scid mice. I421 Interestingly, several diabetes-preven-
tive CD4 T cell clones were found to produce a variety of
cytokines, including type 1 cytokines (IFN, and TNFf), a
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type 2 cytokine (IL-10), and a type 3 cytokine (TGFt). 143-
4sl TGFf was implicated as the mediator of the diabetes-
preventive effects of these islet-reactive CD4 T cell
clones. [44,45] In another study, CD4 T cell lines that react
to rat insulinoma cells and secrete either IFN/or IL-4
were developed from spleens of diabetic NOD mice. I461
The IFN/-secreting CD4 T cells (Thl-type) adoptively
transferred f cell destructive insulitis and diabetes into
neonatal NOD mice, whereas the IL-4- secreting CD4 T
cells (Th2-type) induced a nondestructive peri-islet insuli-
tis. I46] Similarly, Thl cells expressing a diabetogenic T cell
receptor adoptively transferred f cell destructive insulitis
and diabetes in neonatal NOD mice, whereas Th2 cells
expressing the same T cell receptor did not; however, the
Th2 cells did not prevent the Thl cells from transferring
diabetes. I471 This suggests that Th2 cells cannot downreg-
ulate Thl cells whose effector functions (e.g., type 1
cytokine production) are fully differentiated.
In contrast, a subset of natural killer thymocytes
(NKT), TCRaf+CD4CDS, has recently been reported to
prevent adoptive transfer of diabetes by diabetogenic
NOD splenocytes, and protection was related to IL-4
and/or IL-10 production.I481 The protection provided by
the NKT cells is believed to represent diabetes prevention
by correction of an underlying deficiency of NKT
cellsI49,s1 and IL-4 productionlSll in NOD mice. In anoth-
er recent study, a subset of TCRct+CD4+CD62L thymo-
cytes was reported to prevent adoptive transfer of diabetes
by diabetogenic NOD splenocytes, Is21 however, the
cytokine-producing phenotype of these CD4 regulatory T
cells was not determined. Collectively, these studies have
given rise to the concept that the autoimmune response in
type 1 diabetes involves disturbances in immunoregulato-
ry circuits manifested as a dominance of Thl over Th2
cell function and cytokine production (Fig. 2).
According to the scheme depicted in Figure 2, certain
t cell protein(s) act as autoantigens after being processed
by antigen-presenting cells (APCs), such as macrophages,
dendritic cells, and B cells. APCs appear to play an impor-
tant role in the initiation of insulitis. Thus, many studies
indicate that macrophages and dendritic cells are the first
cells to infiltrate pancreatic islets,I53-s51 and inactivation of
macrophages results in the near-complete prevention of
insulitis and diabetes in both NOD mice and BB rats. Is6,s71
Recent studies have found that macrophages play an
essential role in diabetes development in NOD mice by
activating, largely through IL-12 secretion, Thl cells and
CD8 cytotoxic T cells. 158,s91 Also, recent studies have
revealed that B cells clearly influence diabetes develop-
ment in a manner that probably relates to their APC func-
tion, and lack of B cells prevents diabetes development.I6-
62] The immunogenicity of a f cell protein may depend
upon the peptide fragment derived from processing by the
APC, [631 the amino acid sequences of the MHC class II
molecules that bind and present the f cell peptide (anti-
gen), and the precursor frequency of autoreactive T cells
with T cell receptors to match the f cell antigen-MHC
complex. I641 Interestingly, both non-MHC genes I6sl and
MHC class II genesI661 have been reported to. determine
the polarity of the Thl/Th2 immune response in NOD
mice.
In addition to the MHC-antigen complex interaction
with T cell receptors, T cell activation by APCs involves
costimulation through multiple ligand/receptor pairs, e.g.,
B7/CD28, CD40L/CD40, and ICAM-1/LFA-l.I67,681 There
is evidence that APC-T cell interactions via these costimu-
latory molecules are involved in diabetes pathogenesis.
For example, transgenic expression of the costimulator
molecule, B7-1 (CD80) in islet t cells has been shown to
accelerate diabetes in NOD mice. [691 Also, NOD female
mice did not develop diabetes when treated, at the onset
of insulitis (2-4 weeks of age), with CTLA4 immunoglob-
ulin (a soluble antagonist to CD28, the T cell receptor for
the B7 ligand on APCs) or a monoclonal antibody specif-
ic for B7-2 (CD86).[71 In addition, anti-CD40L mono-
clonal antibody treatment of NOD female mice (3-4
weeks of age, but not greater than 9 weeks of age) com-
pletely prevented insulitis and diabetes. 1711 Blockade of
ICAM- 1 and LFA-1 by injection of monoclonal antibod-
ies172,731 or soluble forms of ICAM-1,I741 reduced insulitis
and diabetes incidence in NOD mice, and treatments with
the soluble forms of ICAM-1 were found to decrease IFN,
mRNA expression in the pancreas. 1741
The direction taken by the T cell response, in terms of
Th phenotype, is largely regulated by cytokines. Thus,
naive T cells are not precommitted to any particular Th
phenotype; the Th phenotype varies with the cytokines in
the microenvironment. The presence of IL-12, a
macrophage and B cell product, favors Thl cell differen-
tiation, and anti-IL-12 antiserum blocks expression of the
Thl phenotype.ITSl Indeed, administration of IL-12 to pre-
diabetic NOD female mice was found to accelerate dia-
betes onset, and this was associated with i) enhanced IFN$
and decreased IL-4 production by islet-infiltrating lym-
phocytes, and ii) selective f cell destruction.I761 IL-4, a Th2
and possibly a mast cell product,I771 favors Th2 cell differ-
entiation, and anti-IL-4 monoclonal antibody promotes
expression of a Thl phenotype.I77,781 The results of Thl
cell activation are induction of IL- 2 and IFN production,
inhibition of Th2 cytokine production, and activation of
macrophages, cytotoxic T cells, and natural killer cells.
These activated effector cells may be cytotoxic to islet t








A scheme of the immune system cells and cytokines
believed to mediate destruction of pancreatic islet f cells
in type diabetes. The concept illustrated posits that
certain t cell protein(s) are processed by antigen-pre-
senting cells (APC), such as macrophages and dendritic
cells, then presented as antigen(s) (f-Ag) in a complex
with MHC class II molecules on the surface of the APC.
APC and CD4/ T cells interact via i) the binding of a f-
Ag-MHC II complex on the APC surface to a T cell
receptor (TCR) specific for f-Ag, ii) the binding of cos-
timulator molecules (e.g., B7, CD40, ICAM-1) the
APC surface to their corresponding receptors or ligands
(e.g., CD28, CD40L, LFA- 1) on the T cell, and iii) the
production by the APC of cytokines such as IL-12 that
promote differentiation of CD4/ T cells into Thl-type
cells. Collectively, these interactions, and perhaps oth-
ers, activate CD4/ Thl cells to produce their character-
istic cytokines (IFN3’, IL-2). IFN/i) inhibits CD4/ Th2
cell production of IL-4 and IL-10, and ii) activates
macrophages (M)) and cytotoxic T cells; also, IL-2 acti-
vates cytotoxic T cells. CD8+ T cells are cytotoxic to t
cells following specific recognition of f-Ag on the f cell.
This necessitates direct contact of CD8/ T cells with t
cells via the binding of a CD8/ TCR specific for f-Ag to
the f-Ag-MHC complex on the f cell surface. This T
cell-t cell interaction activates CD8+ T cells, and these
cells may then destroy f cells via i) the binding of Fas
ligand (FasL) on the CD8/ T cell to Fas receptor on
the f cell, and ii) the secretion of cytotoxic molecules,
such as perforin and granzymes. In addition, T cells and
M( may destroy f cells indirectly, that is, the immuno-
logic cells are not in direct contact with f cells and there
is no requirement for specific recognition of f-Ag on f
cells. Rather, activated M( may destroy f cells by pro-
ducing free radicals, such as superoxide (O2"-), hydrogen
peroxide (H202) and nitric oxide (NO’), and cytokines
(IL-1, TNF00 that are cytotoxic to t cells. Also, activat-
ed CD4/ T cells and CD8/ T cells may destroy t cells
by producing cytokines (TNF0, TNFI, IFN3’) that are
cytotoxic to f cells. In addition, cytokines (IL-1, TNF0,
TNFf, IFN,) may i) induce Fas receptors on f cells and so allow CD4/ and CD8/ T cells to destroy the f cells via FasL/Fas-mediated mechanisms, and ii)
increase expression of MHC-I molecules on f cells and so increase interactions of CD8/ T cells and fg cells. Finally, f cell death may result from direct
toxic effects of free radicals (death by necrosis), and from actions of cytokines (IL-1, TNF0, TNFf, IFN3’), FasL/Fas, perforin and granzymes that activate
death signals (e.g., caspase enzymes) in f cells and lead to f cell self- destruction (death by apoptosis and sometimes necrosis). (Reproduced from
Rabinovitch A. Roles of cell-mediated immunity and cytokines in the pathogenesis of Type diabetes mellitus: In Diabetes Mellitus: A Fundamental and
Clinical Text. 2nd edition, 2000, Eds. LeRoith, Taylor, Olefsky, with permission of Lippincott Williams & Wilkins.)
cells through a variety of antigen-specific and nonspecific
mechanisms (Fig. 2).
lmmunostimulatory Procedures
to Prevent Type 1 Diabetes
The concept has been presented above that the autoim-
mune response in type I diabetes involves disturbances in
immunoregulatory circuits that may be manifested as
dominance of Thl over Th2 cell function and cytokine
production (Fig. 2). A corollary of this proposition is that
measures leading to reversal of this Th subset balance,
with Th2 cells/cytokines dominating over Thl
cells/cytokines, should block the autoimmune response
and prevent diabetes development. There is evidence to
support this hypothesis. Thus, administrations of a variety
of "immunostimulants" microbial agents, immune
adjuvants, and T cell mitogens have been discovered to
prevent the development of insulitis, fg cell destruction,
and autoimmune diabetes in genetically diabetes-prone
NOD mice and BB rats. [79-11] Importantly, these
immunostimulatory procedures prevented diabetes devel-
opment without structural changes or complete remodel-
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ling of the immune system unlike
procedures that involve bone mar-
row, thymic, or lymphoid cell
replacement or deletion (e.g., anti-
lymphocyte serum, cyclosporine,
monoclonal antibodies to T cells,
silica, and anti-macrophage anti-
bodies). I81 Rather, the diabetes-pre-
ventive effects of immune adjuvants
have been attributed to stimulation
of T regulatory (suppressor) cells
and cytokines whose effects were to
suppress19s-981 or render dormantI941
autoreactive T cells. Taken togeth-
er, these studies suggest that certain
immunostimulatory procedures
may reset the Th subset balance so
that Th2 cells/cytokines dominate
over Thl cells/cytokines (Fig. 3).
The hypothesis that immunos-
timulatory procedures may prevent
diabetes development in autoim-
mune diabetes-prone rodents by
upregulating Th2 cells/cytokines is
supported by several lines of evi-
dence. Complete Freund’s adjuvant
(CFA)-induced protection of NOD
mice from f cell- destructive insuli-
tis and diabetes was found to be
associated with a relative increase
in IL-4-producing cells and a
decrease in IFNy-producing cells
recovered from "sentinel" syngene-
ic islet grafts placed under the renal
capsule.I1001 However, in a subse-
quent study, it was found that dia-
betes suppression following CFA
administration to diabetes-prone
NOD mice may be mediated only
in part by Th2-type cytokines
because combined anti-IL-4 and
anti-IL-10 antibody treatment
Immunostimulatory procedures:
e.g. cell autoantigens, mitogens,
microbial agents, adjuvants
Th2 celactivation / Thl cell activation
{ MHC-IIB7 / B7v’-II’MHC-II
Th2cytokines 6-Ai IL-10 IL-12 ;-Ag Thl cbl death
Thl cytokines
FIGURE 3
Two distinct mechanisms by which immunostimulatory procedures (e.g., f cell autoantigens, mitogens,
microbial agents, adjuvants), possibly acting via APC stimulation, may prevent or block the autoim-
mune response leading to tg cell destruction in type diabetes. One mechanism may be by Th2 cell acti-
vation. Thus, strong B7-CD28 costimulation during APC-CD4 T cell interactions is thought to favor
differentiation of Th2 over Thl cells. Also, IL-4 and IL-10 induce Th2 over Thl cell differentiation. Th2
cells produce IL-4 and IL-10 which downregulate Thl cells that produce IFNy and IL-2. The combina-
tion of increased IL-4 and IL-10 production and decreased IFNy and IL-2 production inhibits cytotox-
ic M) and T cell activities, thereby preventing fl cell damage and diabetes development. A second mech-
anism by which immunostimulatory procedures may prevent autoimmune tg cell destruction may be by
activating g cell-autoreactive Thl cells along pathways leading to their self-destruction (apoptosis) by
IFNy and IL-2-dependent, FasL/Fas-mediated mechanisms, while Th2 cells that are relatively resistant
to activation-induced cell death would survive. (Reproduced from Rabinovitch A. Roles of cell-mediat-
ed immunity and cytokines in the pathogenesis of Type diabetes mellitus: In Diabetes Mellitus: A
Fundamental and Clinical Text. 2nd edition, 2000. Eds. LeRoith, Taylor, Olefsky, with permission of
Lippincott Williams & Wilkins).
induced a state of glucose intolerance but did not abro-
gate diabetes prevention by CFA.1111 In another study,
treatment of already diabetic NOD mice with CFA at the
time of syngeneic islet transplantation prevented destruc-
tion of tg cells in the islet graft and diabetes did not
recur. 1931 Lymphocytes and monocytes/macrophages still
accumulated around the transplanted islets (peri-islet
insulitis) in the CFA-treated NOD mice, but these
mononuclear cells did not invade the islets and f cells
remained intact. 193i In yet another study, IL-10 mRNA
expression was significantly increased and IL-2 and IFNy
mRNA levels were significantly decreased in syngeneic
islet grafts of CFA-injected NOD mice compared with
saline-injected NOD mice.ll021 This suggested that CFA
treatment upregulated IL-10 production in the islet graft,
resulting in decreased production of Thl cytokines (IL-2
and IFNy) and conversion of a t cell-destructive islet infil-
trate into a nondestructive peri-insulitis lesion. This inter-
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pretation was supported in a subsequent study, in which
the combined administration of IL-10 plus IL-4 (Th2
cytokines) was found to produce significantly prolonged
survival of syngeneic islet grafts in diabetic NOD mice.I13
The diabetes-preventive effects of IL-4 and IL-10 are in
accord with the known actions of these cytokines to
downregulate inflammatory responses mediated by
monocytes/macrophages and their cytokine products, as
well as to downregulate cell-mediated immune responses
triggered by Thl cells and their cytokine products. I34,371
Indeed, IL-4 is consistently diabetes-preventive in NOD
mice, either expressed transgenically by f cells,[141 or
administered systemically. Isll Transgenic studies suggest a
proinflammatory and diabetogenic role for IL-10 when
this cytokine is expressed locally in islets;I1s-171 however,
systemic administrations of IL-10I18,191 and islet-specific
T cells that hyperexpress IL-10 (by gene transfection) II11
have been reported to prevent diabetes development in
NOD mice.
Interestingly, the ability of immunostimulatory proce-
dures, such as microbial agents and immune adjuvants to
promote Th2 over Thl immune responses is concordant
with the concept that the intensity of T cell signalling can
dramatically affect the balance of Thl/Th2 subsets.
According to this "strength of signal" hypothesis, any
reagent or situation that results in strong costimulation of
CD28 receptors on T cells by B7 costimulatory molecules
on APCs will promote Th2 immune responses, whereas
lower intensities of BT/CD28 costimulation will promote
Thl responses. [1111 In support of this hypothesis, diabetes
in NOD mice is exacerbated when the mice are bred onto
the CD28 knockout background as a direct result of a
reduction in the protective Th2 response and concomitant
enhancement of the Thl response. II121 Also, activation of
CD28 signalling in T cells by anti-CD28 monoclonal anti-
body treatment of NOD mice at 2 weeks of age (but not
at 5-6 weeks) was recently reported to increase IL-4 pro-
duction by islet-infiltrating T cells and prevent diabetes
development. II131 These findings suggest that immunos-
timulatory procedures may promote Th2 immune
responses and prevent diabetes by upregulating B7/CD28
costimulation (Fig. 3). Recently, it was reported that B7-1
and B7-2 expression is decreased on dendritic cells in
peripheral blood of humans at high risk for type 1 dia-
betes, and this was accompanied by reduced stimulation
of autologous CD4 T cells.Ill41 Therefore, according to
the strength of signal hypothesis, low levels of B7/CD28
costimulation in individuals at risk for type 1 diabetes
would favor a Thl cell-mediated immune response that
destroys islet t cells at the expense of a protective Th2
response.
Recent studies suggest a novel mechanism for differen-
tial regulation of Thl and Th2 subsets, namely a differen-
tial ability of Thl and Th2 cells to undergo activation-
induced cell death (AICD), also termed apoptosis. Thus,
Thl, but not Th2, cells have been reported to undergo
rapid FasL/Fas-mediated apoptosis after antigen stimula-
tion. II15-11vl Therefore, it is tempting to speculate that
immunostimulatory procedures, such as microbial agents,
adjuvants, mitogens, and tg cell autoantigens, might pre-
vent autoimmune diabetes development by preferentially
inducing apoptosis of autoreactive Thl-type cells (Fig. 3).
According to this scenario, prevention of autoimmune
destruction of G cells would be associated with a decrease
in the ratio of Thl/Th2 cells as a consequence of decreas-
es in Thl cells without any increase in Th2 cells, rather
their selective survival.
Indeed, this has recently been reported to be the mech-
anism of the protective effect of immune adjuvants against
diabetes development in NOD mice. It was found that
BCG and CFA-induced diabetes prevention in NOD mice
persisted in NOD mice genetically deficient in either IL-4
or IL-10, whereas IFN,-deficient NOD mice were not
protected from diabetes by BCG or CFA.II181 Thus,
immune adjuvants protected against diabetes by mecha-
nisms independent of Th2-type cytokines (IL-4 and IL-
l0); rather, the Thl-type cytokine, IFN/was required,
unexpectedly, for immune adjuvant- induced diabetes pre-
vention. The dependency on IFN, for immune adjuvant-
induced diabetes prevention was due, presumably, to dele-
tion of autoreactive Thl cells by IFN/, because NOD Thl
splenic cells were more sensitive to activation-induced cell
death than NOD Th2 splenic cells. II181 Similarly, IFN/,
induced by BCG infection of nondiabetes-prone mice, has
been reported to act as regulator of the immune response
by inducing apoptosis of CD4 T cells initially activated by
BCG.I119]
Anti-T cell antibodies have been found to induce toler-
ance and prevent f cell destruction in NOD mice, even
when the antibodies are administered after insulitis has
started and effector T cells have been activated.[12] The
mechanism of nondepleting anti-CD4 monoclonal anti-
body to induce tolerance in a primed immune system has
been reported to be by activation of CD4 T regulatory
cells,[12H and recently by direct prevention of effector cell
function, presumably by deletion of activated autoreactive
T cells. [1221 Other studies have revealed that induction of
tolerance to cardiac and pancreatic islet allografts in mice
is critically dependent upon IFN
123,1241 and IL-2[125,126]
production. This supports the concept that Thl cell acti-
vation can lead to self-deletion via apoptosis and, conse-
quently, specific T cell tolerance to the stimulating antigen.
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In addition, the protective effect of peripheral NKT
cells against autoimmunity in NOD mice, originally pro-
posed to be due to shifting the profile of autoreactive T
cells toward a protective Th2 type,I271 was recently
reported to be related, instead, to IL-12-induced activa-
tion and IFN, secretion by NKT cells, and these Thl type
immunoregulatory responses were deficient in NOD
mice. I1281 Further evidence that Thl cell activation is
required to prevent autoimmune diabetes development
was provided by a recent study that reported acceleration
of diabetes in NOD mice in which endogenous IL-12 was
neutralized by anti-IL-12 antibody administered to young
NOD mice (2 weeks of age) for 6 days only. I1291 By con-
trast, when anti-IL-12 antibody was administered to older
NOD mice (from age 5 to 30 weeks), insulitis and dia-
betes were suppressed.I291 These findings reveal the dual
role of Thl cytokines (IL-12 and IFNT): i) they act as early
regulators of immune responses, by deleting autoreactive
Thl cells and, if this regulatory action is inadequate and
islet tg cell autoreactive Thl cells persist, then ii) they act
as effectors of f cell destruction.
The aforementioned studies support the general con-
sensus that Thl cells/cytokines are the major disease effec-
tors in autoimmune diabetes,l130-331 and that deletion of
Thl cells or blockade of Thl cell/cytokine actions can
prevent diabetes development. There is conflicting evi-
dence, however, on whether Th2 cells/cytokines have a
protective effect. For example, cotransfer of polarized
Thl and Th2 cells did not inhibit the ability of the Thl
population to provoke diabetes. 14vl Also, NOD mice with
an IL-4 gene knockout mutation did not manifest intensi-
fied insulitis or accelerated diabetes.I341 These findings do
not support the concept that Th2 cells provide dominant
protection against f cell destruction in the insulitis lesion.
This conclusion must be tempered, though, by the fact
that IL-4 knockout mice still produce other Th2 cell-
derived cytokines (e.g., IL-5, IL-IO),13s,361 and possibly
the Th3 cell-derived cytokine, TGFf, any or all of which
could still downregulate Thl cytokine production in IL-4-
deficient NOD mice.
Future Prospects: Clinical Considerations
The clinical hope from observations that certain
immunostimulatory procedures prevent autoimmune dia-
betes development in genetically diabetes-prone animals is
that clinically safe means of immune stimulation may be
similarly effective in preventing type 1 diabetes in human
subjects at risk for this disease. Immunostimulatory
agents that have a broad spectrum of immune stimulation
affecting macrophages and T cells (e.g., the immune adju-
vant, bacille Calmette-Gu6rin [BCG] vaccine) and poly-
c|onal T cell activators (e.g., microbial superantigens,
lectins) may not be optimal for clinical trials because of
possible undesirable side effects from generalized
immunostimulation.
Recent findings, however, demonstrate that more selec-
tive immunostimulation may be at hand. Thus; adminis-
tration of the peptide GAD65, an islet f cell autoantigen,
can prevent autoimmune diabetes development in NOD
mice, and this prevention is associated with the induction
of specific tolerance to this peptide.37,38 Moreover,
GAD-responsive T cells from diabetes-prone NOD mice
were characterized as Thl, IFN,-producing.I371 In con-
trast, IFN/production was reduced in antigen-stimulated
spleen cell cultures from GAD65-tolerant (and diabetes-
protected) NOD mice, indicating that tolerance may
result from suppression of GAD65-responsive Thl
cells.I381 Because this effect was not accompanied by a
corresponding reduction of the humoral (antibody)
response to GAD and other t cell autoantigens, a GAD65
induction of Th2 cells with suppression of Thl cells was
suggested. I381 Importantly, GAD65 administration to
NOD mice was reported to suppress an ongoing diabeto-
genic response (late insulitis, prehyperglycemic stage of
type 1 diabetes), and this protection was mediated
through the induction of regulatory CD4 T cells with a
Th2 phenotype,l391 Furthermore, induction of GAD65-
specific Th2 cells and suppression of diabetes in NOD
mice is IL-4 dependent, because NOD mice genetically
deficient in IL-4 production (IL-4 gene knockout NOD
mice) were not protected from diabetes development after
immunization with GAD65-specific peptides,I41 or a
novel plasmid DNA construct encoding both a GAD65
peptide linked to IgG Fc and IL-4.I4l These findings are
directly relevant to reports that there is an inverse relation
between humoral (Th2 cell-mediated) and cellular (Thl
cell-mediated) autoimmunity to GAD in human subjects
at risk for type 1 diabetesI1421 and that a strong humoral
(serum antibody) response to GAD correlates with a slow
progression to diabetes. I142,431
Administration of tg cell candidate autoantigens other
than GAD may also induce self- tolerance and prevent
diabetes development. For example, insulin (and insulin B
chain) can prevent diabetes inNOD mice and BB rats, and
possibly in human subjects at high risk for type 1 dia-
betes. [1441 Recently, a T cell response to a particular epi-
tope of the insulin B chain, B(9_23) was described in periph-
eral blood lymphocytes obtained from human subjects
with recent-onset type 1 diabetes and from prediabetic
subjects at high risk for disease, and these T cells pro-
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duced IFN,.I1451 The significance of these findings is that
therapies that are directed at this autoantigenic response
might be of benefit in controlling human type 1 diabetes,
as was achieved by administration of the B chain or B(lo_
24) peptide of insulin in NOD mice. 1146,1471 In addition,
reports that NOD mice can be protected from diabetes
development by administering the f cell autoantigens,
GADI48,491 and insulinl46,47,5q541 by oral, intranasal or
aerosol inhalation routes may be of practical importance
for clinical application. The mechanisms of the protective
effects of these treatments in NOD mice have been
ascribed to activation of CD4 0tf T cells or CD8 /15 T
cells that produced one or more suppressor cytokines (IL-
4, IL-10 and TGFtg).
Immune-mediated destruction of insulin-secreting f
cells precedes the overt expression of clinical symptoms by
many years because these become apparent only when a
majority of the tg cells have been destroyed. Interrupting
this pathogenetic sequence by immune intervention offers
the opportunity to alter the natural history of type 1 dia-
betes. Several approaches are currently being explored in
clinical trials or are under consideration for such trials.
These include the following therapeutic approaches used
singly or in combination: i) administration of f cell
autoantigens (e.g., insulin) via parenteral, oral, nasal or
aerosol inhalation routes; ii) manipulation of expression
of costimulatory molecules (e.g., B7/CD28,
CD40/CD40L) on antigen-presenting cells and T cells in
attempts to delete autoreactive Thl cells or direct T cell
signalling pathways from Thl to Th2 cell dominance; and
iii) administration of cytokine-based therapies (e.g.,
cytokines, antibodies to cytokines and cytokine receptors,
soluble cytokine receptors and receptor antagonists,
cytokine receptor-targeted cytotoxic drugs) to block the
production and/or action of proinflammatory cytokines
(IL-1 and TNF0t) and type 1 cytokines (IFN,, IL-2, TNFt
and IL-12), while maintaining or increasing the produc-
tion and/or action of regulatory cytokines (IL-4, IL-10,
TGFf).
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